Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.
Tannaz Armaghany, MD
Advertisement
Articles by Tannaz Armaghany, MD
Tannaz Armaghany, MD, discusses sorafenib versus lenvatinib as first-line therapy for patients with hepatocellular carcinoma.
Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.
Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Armaghany on Gene Sequencing in CRCPublished: March 13th 2020 | Updated:
Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRCPublished: March 26th 2020 | Updated:
Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Unresectable HCCPublished: April 4th 2020 | Updated:
Dr. Armaghany on the Utility of ctDNA in CRCPublished: June 4th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5